The first sublingual esketamine film designed for PTSD — targeting both psychological symptoms and neuroinflammation.
*Sertraline (1999) and paroxetine (2001) are the only FDA-approved PTSD medications. Both are 1990s SSRIs. No novel mechanism has been approved in over 25 years. Sources: FDA, SAMHSA, Grand View Research.
Emerging evidence shows that PTSD is associated with chronically elevated levels of pro-inflammatory cytokines — including IL-6, TNF-α, and CRP — that persist long after the traumatic event. These biomarkers disrupt hippocampal neurogenesis, impair BDNF signaling, and perpetuate the hyperarousal and avoidance symptoms that define the disorder.
Existing pharmacotherapies — SSRIs, SNRIs, prazosin — address neurotransmitter balance but leave the inflammatory substrate largely untreated. This is a core reason why 40–60% of PTSD patients fail to achieve remission.
3.6 million treatment-resistant PTSD patients have already exhausted every approved option. Only 2 FDA-approved drugs exist for the primary indication — both over 20 years old — and neither addresses the neurobiological substrate.
Passos et al. (2015). "Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression." JAMA Psychiatry, 72(2), 192–200. Meta-analysis of 20 studies, N>1,000.
Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression — not PTSD. While its mechanism is highly relevant, its in-clinic model and $6,000–8,000/month price tag create a prohibitive access barrier. Meanwhile, unregulated compounded troches ($100–150/month, no oversight, dissociative doses) fill the vacuum with no FDA path, no insurance pathway, and no standardized safety monitoring.
The gap between Spravato and unregulated troches is where Project Lucid lives: FDA-regulated, low-dose, at-home, and designed from the ground up for PTSD.
The competitive landscape shifted materially in August 2024, when the FDA rejected MDMA-assisted therapy for PTSD — the most high-profile novel approach in years — citing data integrity concerns and functional unblinding limitations inherent to psychedelic trials. The rejection underscores investor demand for candidates with cleaner, placebo-controlled evidence packages. Ketamine’s RCT record in PTSD is precisely that.
Project Lucid's 50mg sublingual esketamine film operates through two complementary mechanisms simultaneously — rapid neuroplasticity induction and direct anti-inflammatory action — neither of which existing treatments address together.
Durability comes from frequency — not dose. The field is optimizing for intensity. We're optimizing for durability.
NMDA receptor antagonism triggers downstream BDNF release, promoting synaptogenesis in the prefrontal cortex and hippocampus within hours — not weeks.
Esketamine directly suppresses pro-inflammatory cytokines IL-6 and TNF-α — addressing the neuroinflammatory substrate that conventional PTSD treatments leave untreated.
Sublingual film achieves ~29% bioavailability with rapid Tmax (~19 min) — parent-drug Cmax comparable to Spravato 56–84mg intranasal — without requiring in-clinic administration after the first supervised dose.
| Dimension | Project Lucid | Spravato (J&J) | IV Ketamine Clinics |
|---|---|---|---|
| Delivery | Sublingual film | Nasal spray | Intravenous infusion |
| Active Ingredient | Esketamine (50mg) | Esketamine (56–84mg) | Racemic ketamine |
| Setting | At-home after first clinic dose | In-clinic only (2-hr monitoring) | In-clinic only (45–60 min infusion) |
| Dosing Frequency | 3×/week | 2×/week → 1×/week maintenance | Varies (1–2×/week) |
| PTSD Indication | Primary target | Not indicated (TRD only) | Off-label |
| Neuroimmune Mechanism | Core thesis: dual-pathway | Not positioned | Not positioned |
| Dose Level | Sub-dissociative | Can be dissociative | Often dissociative |
| Cost Model | Designed for accessibility | ~$900/session (before insurance) | $400–800/infusion |
| Reimbursement Target | Insurance-reimbursable target | Limited (specialty pharmacy) | Rarely covered |
Project Lucid is an IRB-ready Phase 1 pilot — N=12 — studying 50mg sublingual esketamine 3×/week for 4 weeks in adults with PTSD. Each milestone below represents an investor catalyst event.
Protocol LUCID-PTSD-2026-001 is IRB-ready. Study design, inclusion/exclusion criteria, safety monitoring plan, and informed consent documents are complete. IRB submission and approval targeted Q3 2026.
ActiveEnrollment of N=12 adults with confirmed PTSD diagnosis (CAPS-5 ≥ 26) and stable comorbid medication regimen. Baseline biomarker panel (IL-6, TNF-α, CRP, BDNF) and symptom scales collected.
First reportable data: adverse event profile, tolerability at 50mg SL dose, early biomarker trends. DSMB review of safety data. Interim PCL-5 and CAPS-5 signals presented.
Full primary outcome data: CAPS-5 change from baseline (primary), PCL-5 (secondary), inflammatory biomarker panel change, PSQI sleep quality. Results prepared for scientific conference presentation.
Investigational New Drug application filing and FDA pre-submission meeting request. Successful pilot data supports Phase 2 design and partnership/out-licensing discussions.
All dosing sessions include 2-hour post-dose digital monitoring with validated dissociation assessment (CADSS at 40 minutes) and vital sign tracking. Explicit discharge criteria gate home release. C-SSRS suicidality screening at every visit. DSMB review after the first 6 patients. Stopping rules for any serious adverse event. The safety protocol was designed to demonstrate clinical viability — not just regulatory compliance.
The case for Project Lucid is not speculative — it rests on a converging body of clinical, pharmacokinetic, and mechanistic evidence. Repeated IV ketamine 3×/week produces PTSD response rates of 67–77% with Cohen's d up to 1.9. The 50 mg SL OTF achieves parent-drug Cmax comparable to Spravato 56–84 mg. And at-home sublingual ketamine has a robust real-world safety record across 11,441 patients.
Protocol: 6 IV infusions (0.5 mg/kg), 3×/week × 2 weeks. Directly establishes the 3×/week schedule as evidence-based for PTSD.
View on PubMedAmong the largest effect sizes ever reported in psychiatric pharmacotherapy. Project Lucid's digital platform is designed to deliver this combination model at home.
View on PubMed CentralThe 50 mg SL OTF — the same LTS Lohmann platform underlying Project Lucid — was characterized in a Phase 1 PK trial by Dahan et al. (2022). The key finding: the OTF achieves parent-drug S-ketamine Cmax of ~96 ng/mL, comparable to Spravato 56–84 mg intranasal — not half a Spravato 28 mg, as the lower systemic AUC might suggest.
| Parameter | 50 mg SL OTF Project Lucid |
Spravato 28 mg IN | Spravato 56 mg IN | Spravato 84 mg IN |
|---|---|---|---|---|
| Bioavailability | ~29% | ~48% | ~48% | ~48% |
| Systemic S-ket delivered | ~14.5 mg | ~13.4 mg | ~26.9 mg | ~40.3 mg |
| S-ketamine Cmax (ng/mL) | ~96 | 43.8 | 72.5 | 101.0 |
| S-norketamine Cmax (ng/mL) | ~276 | 59.1 | 119.7 | 180.0 |
| Norketamine : Ketamine ratio | ~4.6× | ~1.4× | ~1.7× | ~1.8× |
| Tmax (min) | ~19 | 20–40 | 20–40 | 20–40 |
Source: Dahan et al. 2022 (OTF); J&J / FDA Clinical Pharmacology Review (Spravato). IN = intranasal. Spravato bioavailability includes nasal + GI components.
The SL route’s heavy hepatic first-pass metabolism generates a pharmacologically advantageous metabolite profile. S-norketamine Cmax (276 ng/mL) is 4.6× the parent drug — vs. 1.4–1.8× for Spravato intranasal. The OTF also generates meaningful S-hydroxynorketamine (S-HNK, Cmax ~101 ng/mL), essentially absent in intranasal delivery. Both metabolites carry independent antidepressant and synaptogenic activity without dissociative or abuse-related properties. The SL route is not a compromise — it is a feature.
An honest appraisal of what is known, what is inferred, and what gap Project Lucid fills.
| Scientific Dimension | Evidence Level | Key Sources |
|---|---|---|
| PTSD unmet need | Strong | VA/DoD CPG 2023; PTSD market data |
| Ketamine efficacy in PTSD (3×/week IV) | Strong (RCT) | Feder 2021, Feder 2025 |
| 50 mg OTF pharmacokinetics | Strong (Phase 1) | Dahan et al. 2022 |
| Therapeutic dose adequacy of 50 mg OTF | Moderate-Strong | Cmax ~96 ng/mL comparable to Spravato 56–84 mg |
| S-HNK / S-norketamine metabolite activity | Moderate | Zanos 2016; Bottemanne 2025 review; Phase 1 HNK trial |
| 3×/week schedule neuroplasticity rationale | Strong | ASL imaging; Singh et al.; Feder protocols |
| Fear reconsolidation mechanism | Moderate (Phase 2) | Morrison et al. 2023 |
| At-home SL ketamine safety (N=11,441) | Strong (prospective) | Wolfson et al. 2023; Mindbloom PTSD data |
| Long-term esketamine safety (129 sessions) | Moderate (N=20) | Bozan et al. 2026; SUSTAIN-3 |
| SL esketamine efficacy specifically in PTSD | Absent — gap we fill | N/A — rationale by extrapolation. This is what LUCID-PTSD-2026-001 directly addresses. |
Pivotal RCT establishing 3×/week ketamine as evidence-based for PTSD. 67% vs. 20% response rate; d=1.13; CAPS-5 reduction of 11.9 points vs. 2.4 for midazolam.
View on PubMedOpen-label trial combining 3×/week IV ketamine with WET. d=1.9 — among the largest effect sizes in psychiatric pharmacotherapy. 69% response at Week 12; 61.5% no longer meeting DSM-5 criteria at 6 months.
View on PMCPhase 1 PK trial of the LTS 50 mg S-ketamine OTF. Establishes ~29% bioavailability, Cmax ~96 ng/mL (comparable to Spravato 56–84 mg), and the 4.6× norketamine metabolite advantage.
View on PMCRandomized crossover study (N=27) showing ketamine after trauma memory reactivation significantly reduced amygdala reactivity to trauma cues at 30-day follow-up. Direct evidence that ketamine can rewrite traumatic memories during the reconsolidation window.
View on NatureLargest prospective safety dataset for sublingual ketamine. At average doses 7× the Project Lucid dose: adverse events 3–5%, serious adverse events 0.05%, intense dissociation requiring discontinuation 0.1%. No drug-related fatalities.
View on PMCMost comprehensive long-term esketamine safety data to date: 20 TRD patients, mean 129 intranasal sessions over 2.5 years. No serious adverse events. Side effects mild and transient at all sessions. 85% of patients improved after 129 sessions.
View on PMCMeta-analysis of 20 studies (N>1,000) demonstrating significantly elevated IL-6, IL-1β, and CRP in PTSD. Establishes the neuroinflammatory substrate that esketamine directly targets through cytokine suppression.
View on PubMedComprehensive review of NMDA receptor antagonism, downstream BDNF upregulation, and AMPA potentiation. Establishes that the therapeutic mechanism extends well beyond glutamate modulation and supports the rationale for repeated sub-dissociative dosing.
View on PubMedReal-world dataset of 1,247 patients receiving at-home sublingual ketamine. Significant improvement at 1, 2, and 3 months. Directly validates Project Lucid’s delivery route and monitoring model at scale.
View on PubMed6-week low-dose oral ketamine trial in 25 PTSD patients. Confirmed BDNF and VEGF-A changes — the first comprehensive biomarker evidence that oral ketamine drives neuroplasticity-mediated PTSD symptom reduction. Direct biological analog to Project Lucid’s sublingual delivery model.
Double-blind, active-controlled crossover RCT in 33 treatment-resistant PTSD patients. IM ketamine vs. fentanyl (psychoactive control). Ketamine at 1 mg/kg produced substantial, sustained PTSD severity reduction (IESR). Confirms efficacy even against an active psychoactive comparator — ruling out placebo or expectancy effects.
Dallas-based psychiatrist and PTSD specialist who developed Project Lucid directly from clinical ketamine experience. Sponsor-Investigator of LUCID-PTSD-2026-001 — an IRB-ready Phase 1 pilot of 50mg sublingual esketamine for PTSD.
The clinical premise of Project Lucid sits at the intersection of three bodies of evidence that have not previously been connected: Feder et al.’s RCT-validated 3×/week IV ketamine protocol, Dahan et al.’s Phase 1 PK characterization of the 50mg SL OTF, and Wolfson et al.’s at-home safety dataset of N=11,441. The synthesis is Dr. Idell’s.
Protocol LUCID-PTSD-2026-001 is patent-pending (formulation and protocol), IRB-ready, and targeting Q4 2026 enrollment. Dr. Idell is the Sponsor-Investigator.
Dr. Mukesh Kumar, PhD, RAC
CEO & Founder, FDAMap — Washington, DC. 20+ years in FDA regulatory affairs. 150+ clinical trials across 34 countries. Confirmed 505(b)(2) pathway viability for Project Lucid.
Dr. Steven Idell, MD, PhD
Pulmonary & Critical Care Physician. Temple Chair in Pulmonary Fibrosis. 40 years of continuous NIH funding. Founder of Lung Therapeutics (acquired → Rein Therapeutics). Deep translational drug development expertise.
EMMES Corporation
Full-service CRO engaged for Phase 1 pilot study design. Specializes in Phase I–IV trials, biostatistics, pharmacovigilance, and FDA regulatory affairs. AI-enabled trial management.
PTSD represents one of the largest untapped markets in psychiatry. No biologic holds a PTSD primary indication. No novel mechanism has been approved in 25 years. The MDMA path was closed by the FDA in 2024. The window for a well-evidenced, cleanly-executed ketamine candidate has not been wider.
Whether you're evaluating an investment or exploring a clinical collaboration, we welcome direct conversations.
Seed-stage funding opportunity. Supporting Phase 1 pilot completion, biomarker data collection, and IND preparation. Reach out to receive the full investor deck, protocol summary, and financial projections.
Academic medical center partnerships, site collaboration, and key opinion leader engagement. Trauma psychiatrists, psychopharmacologists, and drug delivery researchers are welcome to reach out about the science and study design.
